About Ascendis Pharma
Ascendis Pharma is a company based in Hellerup (Denmark) founded in 2007. Ascendis Pharma has raised $108.7 million across 3 funding rounds from investors including Orbimed, Janus Henderson Investors and RA Capital. Ascendis Pharma operates in a competitive market with competitors including Moderna, Merck, Roivant Sciences, BeiGene and AbbVie, among others.
- Headquarter Hellerup, Denmark
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ascendis Pharma A/S Sponsored Adr
-
Annual Revenue
$393.35 M (USD)36.41as on Dec 31, 2024
-
Net Profit
-$408.97 M (USD)21.43as on Dec 31, 2024
-
EBITDA
-$282.37 M (USD)40.18as on Dec 31, 2024
-
Total Equity Funding
$108.7 M (USD)
in 3 rounds
-
Latest Funding Round
$60 M (USD), Series D
Nov 24, 2014
-
Investors
Orbimed
& 11 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ascendis Pharma
Ascendis Pharma is a publicly listed company on the NASDAQ with ticker symbol ASND in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Ascendis Pharma
Unlock access to complete
Unlock access to complete
Leadership Team
98 people
Software Development Team
46 people
Product Management Team
44 people
Senior Team
32 people
Finance and Accounting
28 people
Sales and Marketing
21 people
Operations Team
14 people
Legal and Compliance
11 people
Unlock access to complete
Funding Insights of Ascendis Pharma
Ascendis Pharma has successfully raised a total of $108.7M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $60 million completed in November 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series D — $60.0M
-
First Round
First Round
(13 Dec 2007)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2014 | Amount | Series D - Ascendis Pharma | Valuation | Sofinnova Investments , Orbimed | |
| Jun, 2010 | Amount | Series B - Ascendis Pharma | Valuation |
investors |
|
| Dec, 2007 | Amount | Series A - Ascendis Pharma | Valuation | Gilde Healthcare , TechnoStart |
|
Investors in Ascendis Pharma
Ascendis Pharma has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Janus Henderson Investors and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ascendis Pharma
Financial Statements - Ascendis Pharma
Ascendis Pharma Comparisons
Competitors of Ascendis Pharma
Ascendis Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Merck, Roivant Sciences, BeiGene and AbbVie, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| domain | founded_year | HQ Location |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
Frequently Asked Questions about Ascendis Pharma
Ascendis Pharma was founded in 2007.
Ascendis Pharma is headquartered in Hellerup, Denmark.
Jan Moller Mikkelsen is the current CEO of Ascendis Pharma.
Ascendis Pharma is a funded company, having raised a total of $108.7M across 3 funding rounds to date. The company's 1st funding round was a Series A of $25.8M, raised on Dec 13, 2007.
Annual revenue of Ascendis Pharma is $393.35M as on Dec 31, 2024.
Ascendis Pharma was founded in 2007 in Hellerup, Denmark, as a biopharmaceutical company focused on prodrug technologies. Unmet medical needs are addressed through a pipeline that includes TransCon human growth hormone for growth hormone deficiency in adults and children, TransCon Treprostinil for pulmonary arterial hypertension, TransCon Insulin for diabetes, and TransCon Ranibizumab for age-related macular edema. Strategic collaborations are maintained with Sanofi and Genentech to support development efforts.
Ascendis Pharma's top competitors include Merck, Moderna and Roivant Sciences.
Yes, Ascendis Pharma is publicly traded on NASDAQ under the ticker symbol ASND.
Ascendis Pharma has 12 investors. Key investors include Orbimed, Janus Henderson Investors, RA Capital, Sofinnova, and Venrock.
The ticker symbol of Ascendis Pharma is ASND on NASDAQ.